eli lilly glp-1 FDA approval for Zepbound (tirzepatide) injection, the first and only obesity treatment of its kind that activates both GIP and hormone receptors - Lilly is now pharma's top
Description
Mounjaro and Ozempic both help control blood sugar and promote weight loss in people with diabetes
The development of dual GIPRGLP1R coagonists that bind to either one or the other receptor (sequence-mixed dual agonists) has emerged as an innovative therapeutic strategy for obesity and type 2 diabetes
Understanding the mechanism helps you manage symptoms effectively while pursuing weight loss goals
The primary outcome was change in HbA1c from baseline
Click here to see which areas are affected.
